Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.

dc.contributor.authorJiménez-Cortegana, Carlos
dc.contributor.authorSánchez-Martínez, Pilar M
dc.contributor.authorPalazón-Carrión, Natalia
dc.contributor.authorNogales-Fernández, Esteban
dc.contributor.authorHenao-Carrasco, Fernando
dc.contributor.authorMartín García-Sancho, Alejandro
dc.contributor.authorRueda, Antonio
dc.contributor.authorProvencio, Mariano
dc.contributor.authorde la Cruz-Merino, Luis
dc.contributor.authorSánchez-Margalet, Víctor
dc.date.accessioned2025-01-07T16:16:06Z
dc.date.available2025-01-07T16:16:06Z
dc.date.issued2021-09-15
dc.description.abstractThe search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have recently found that the level of circulating MDSCs is a good marker of survival in a translational study based on a trial (EudraCT Number: 2014-001620-29), using lenalidomide combined with R-GDP (rituximab plus gemcitabine, cisplatin, and dexamethasone). Since Vitamin D is a known immunomodulator, we have studied blood levels of these cell populations comparing patients with deficit of vitamin D levels (15 ng/mL. Mann-Whitney U test was used to compare cells distributions between groups, Wilcoxon test to compare cells distribution at different times and Spearman test to measure the association between cell populations. Patients with vitamin D deficit maintained the increased level of immune suppressor cells, whereas we observed a depletion of all immune suppressor cells in patients with normal vitamin D levels. In conclusion, we have confirmed the importance of vitamin D in the response to treatment in R/R DLBCL, suggesting that vitamin D deficit may be involved in the immune deficit of these patients, and thus, vitamin D supplementation in these patients may help to obtain a better response, warranting further investigation.
dc.identifier.doi10.3390/cancers13184622
dc.identifier.issn2072-6694
dc.identifier.pmcPMC8471526
dc.identifier.pmid34572849
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8471526/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/13/18/4622/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27720
dc.issue.number18
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.organizationSAS - Hospital Costa del Sol
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectMDSC
dc.subjectPD-1
dc.subjectTreg
dc.subjectdiffuse large B-cell lymphoma
dc.subjectimmune system
dc.subjectimmunosuppression
dc.subjectlenalidomide
dc.subjectvitamin D
dc.titleLower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8471526.pdf
Size:
15.06 MB
Format:
Adobe Portable Document Format